Essa terminates an N-terminal journey
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
FDA red and green lights: October 2024
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Clouds loom for Novartis’s MorphoSys buy
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
Triple meeting 2024 – Revolution shows selective KRAS promise
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
